Jarurat Care Foundation shared a post on LinkedIn:
“HORIZON | Edition III – On the Horizon.
A Global Collaborative Forum on Cancer Care.
How do clinicians make therapy decisions for unresectable hepatocellular carcinoma in the era of immunotherapy?
An insightful and impactful discussion on “How Do We Choose Therapy for Unresectable HCC in the Era of Immunotherapy?”, bringing together global expertise, regional perspectives, and real-world clinical experience.
International Keynote Speaker: Dr. Renuka Iyer (Roswell Park Comprehensive Cancer Center, NCCN) shared insights on evolving immunotherapy strategies, emerging clinical trials, and future systemic therapies.
From immunotherapy strategies to emerging clinical trials and future systemic therapies, HORIZON Edition III reinforced the power of collaboration in shaping better outcomes for patients with hepatocellular carcinoma.
Featuring leading oncologists from:
MD Anderson Cancer Center, Roswell Park Comprehensive Cancer Center, Sir H.N. Reliance Foundation Hospital and Research Centre, CARE Hospitals, Quality CARE India Limited, M | O | C Cancer Care and Research Centre, and more.
We are grateful to all speakers, panelists, and attendees who made this exchange of knowledge thoughtful, meaningful, and impactful.
Together, we learn. Together, we move cancer care forward.
In association with:
AstraZeneca, Roswell Park Comprehensive Cancer Center, Sir H.N. Reliance Foundation Hospital and Research Centre, CARE Hospitals, Quality CARE India Limited, Dr. Milind Javle, Dr. Sewanti Limaye, MBBS, MD, MS, Dr. Darshit Shah, Dr. Tushar Patil, Dr Ravi Jaiswal, HOC Vedanta, Dr. Prashant Jambunathan.”
More posts featuring Renuka Iyer on OncoDaily.
